PuSH - Publikationsserver des Helmholtz Zentrums München

Gastaldelli, A.* ; Stefan, N. ; Häring, H.-U.

Liver-targeting drugs and their effect on blood glucose and hepatic lipids.

Diabetologia, DOI: 10.1007/s00125-021-05442-2 (2021)
Verlagsversion DOI
Open Access Gold (Paid Option)
Creative Commons Lizenzvertrag
The global epidemic of non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) and the high prevalence among individuals with type 2 diabetes has attracted the attention of clinicians specialising in liver disorders. Many drugs are in the pipeline for the treatment of NAFLD/NASH, and several glucose-lowering drugs are now being tested specifically for the treatment of liver disease. Among these are nuclear hormone receptor agonists (e.g. peroxisome proliferator-activated receptor agonists, farnesoid X receptor agonists and liver X receptor agonists), fibroblast growth factor-19 and -21, single, dual or triple incretins, sodium-glucose cotransporter inhibitors, drugs that modulate lipid or other metabolic pathways (e.g. inhibitors of fatty acid synthase, diacylglycerol acyltransferase-1, acetyl-CoA carboxylase and 11β-hydroxysteroid dehydrogenase type-1) or drugs that target the mitochondrial pyruvate carrier. We have reviewed the metabolic effects of these drugs in relation to improvement of diabetic hyperglycaemia and fatty liver disease, as well as peripheral metabolism and insulin resistance.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Farnesoid X Receptor Agonists ; Fibrosis ; Hepatokines ; Incretins ; Insulin Resistance ; Non-alcoholic Fatty Liver Disease ; Non-alcoholic Steatohepatitis ; Peroxisome Proliferator-activated Receptor (ppar) Agonists ; Review ; Sglt2 Inhibitors; Type-2 Diabetes-mellitus; Improves Insulin Sensitivity; Cotransporter 2 Inhibitor; Glucagon-like Peptide-1; X-receptor Agonist; Placebo-controlled Trial; Tyrosine-phosphatase 1b; Fatty Liver; Nonalcoholic Steatohepatitis; Double-blind
ISSN (print) / ISBN 0012-186X
e-ISSN 1432-0428
Zeitschrift Diabetologia
Verlag Springer
Verlagsort Berlin ; Heidelberg [u.a.]
Begutachtungsstatus Peer reviewed
Förderungen Consiglio Nazionale delle Ricerche